ONO PHARMACEUT.
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules f… Read more
Market Cap & Net Worth: ONO PHARMACEUT. (ON4)
ONO PHARMACEUT. (F:ON4) has a market capitalization of $6.13 Billion (€5.97 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #2464 globally and #204 in its home market, demonstrating a -4.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ONO PHARMACEUT.'s stock price €12.70 by its total outstanding shares 469907657 (469.91 Million).
ONO PHARMACEUT. Market Cap History: 2021 to 2026
ONO PHARMACEUT.'s market capitalization history from 2021 to 2026. Data shows change from $10.32 Billion to $6.13 Billion (-7.15% CAGR).
ONO PHARMACEUT. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ONO PHARMACEUT.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ON4 by Market Capitalization
Companies near ONO PHARMACEUT. in the global market cap rankings as of March 18, 2026.
Key companies related to ONO PHARMACEUT. by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
ONO PHARMACEUT. Historical Marketcap From 2021 to 2026
Between 2021 and today, ONO PHARMACEUT.'s market cap moved from $10.32 Billion to $ 6.13 Billion, with a yearly change of -7.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €6.13 Billion | +10.43% |
| 2025 | €5.55 Billion | +19.17% |
| 2024 | €4.65 Billion | -38.14% |
| 2023 | €7.52 Billion | -27.10% |
| 2022 | €10.32 Billion | 0.00% |
| 2021 | €10.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of ONO PHARMACEUT. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.13 Billion USD |
| MoneyControl | $6.13 Billion USD |
| MarketWatch | $6.13 Billion USD |
| marketcap.company | $6.13 Billion USD |
| Reuters | $6.13 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.